GLP-1 Costs: A Heavy Burden—Or a Better Path Forward

Why employers are paying more than ever 

GLP‑1 drugs— such as semaglutide (Ozempic, Wegovy) and tirzepatide ( Mounjaro)—are rapidly becoming some of the most prescribed some of the most prescribed treatments for  diabetes, obesity, and related chronic conditions. But their financial impact on employer health plans is growing fast: 

In 2024, GLP‑1 medications made up 10.5% of annual insurance claims—up from 6.9% in 2022. Some employers reported that GLP‑1s accounted for more than 15% of total claims.  

Employers with employees using GLP‑1s saw an average increase in annual costs per person of nearly $7,800 per employee. 

These explosive costs are driving up premiums, straining budgets, and leading nearly 1 in 3  employers to consider dropping coverage entirely. 

The RevDoc Platform: The Smarter Path to GLP-1 Access 

With the direct-pay model on the RevDoc platform, GLP-1  access can be simpler, more cost-effective, and more transparent. Instead of navigating the complexity of PBMs and unpredictable insurance claims, employees gain a clearer path to treatment options—and employers gain financial predictability. 

By reducing administrative layers and  streamlining access, the RevDoc platform helps minimize  friction, lowers the risk of  surprise claims, and makes it easier for companies to offer GLP-1 options  as part of a modern, forward-thinking health strategy. 

The impact is clear: improved access for employees, more sustainable costs for employers, and a benefit that demonstrates a genuine investment in your workforce. 

With the RevDoc platform, employers gain clarity and control. Employees gain easier access to providers and treatment options.  Together, it supports a pathway toward stronger workforce health.

Why the Direct-Pay for GLP-1 Model on RevDoc Works 

• Lower costs 
  Employers can see meaningful reductions in spend per patient per year.  

• Improved access, stronger engagement 
  With pricing and access simplified, employees are more  likely to stay satisfied and engaged with their care. 

• Budget confidence 
  Minimize surprise claims. Subsidies are predictable, giving employers  greater financial visibility and control. 

• Modern benefit culture 
  Offering innovative, equitable health options signals that you care—building loyalty and supporting talent attraction. 
  
  

In the face of rising costs and unpredictable claims, it's time to rethink your approach. 

With the direct-pay  GLP-1 model available on RevDoc, employers can support lower costs, clear value, and better employee access—all while aligning with  responsible, high-quality care. 

Ready to switch to smarter GLP-1 access? 
Explore RevDoc for Employers →